Home
Live Updates
Ivonescimab In Combination With Chemotherapy Approved In China By NMPA For 2L+ Egfrm NSCLC Based On Harmoni-A Clinical Trial: Positive Trend Observed ... : comparemela.com
Ivonescimab In Combination With Chemotherapy Approved In China By NMPA For 2L+ Egfrm NSCLC Based On Harmoni-A Clinical Trial: Positive Trend Observed ...
Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0
Related Keywords
China ,
,
Prnewswire Akeso Inc ,
National Medical Products Administration ,
Showed Clinically Meaningful ,
Statistically Significant Benefit ,
Patients Previously Receiving ,
Adverse Events ,
Treatment Discontinuation ,
Oral Presentation ,
Manuscript Published ,
comparemela.com © 2020. All Rights Reserved.